Companies: 10,795·Total market cap: $144.5T
Grace Therapeutics, Inc.

Grace Therapeutics, Inc.

GRCENASDAQHealthcare● Active
$2.30
+$0.00(+0.00%)
Market Cap$35590200
P/E Ratio
52W High$5.18
52W Low$1.79
Overview

Grace Therapeutics, Inc. (GRCE) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · GRCE · as of Jun 9, 2026

Key Statistics

EPS (TTM)$-0.50grce eps ttm · grce earnings per shareEarnings history
PE Ratio (TTM)grce pe ratio ttm · grce price to earningsPE Ratio deep dive
Revenue (TTM)0.00grce revenue ttm · grce annual revenueFull revenue history
Dividend YieldNo Dividenddoes grce pay dividends · grce dividend yieldDividend history
Shares Outstanding12.1Mgrce shares outstanding · grce floatShares outstanding history
Next EarningsJun 22, 2026Est.grce earnings date · grce next earningsEarnings history

Financial Snapshot

Full Financials
FY 2025Revenue$0.00
202320242025
grace therapeutics, inc. revenue · grce revenue 2025
FY 2025Net Income-$13.6M▲ +21.88% YoY
202320242025
grace therapeutics, inc. net income · grce profit 2025
FY 2025EPS$-1.13▲ +38.25% YoY
202320242025
grce eps · grace therapeutics, inc. earnings per share 2025
TTM:Revenue: $0.00Net Income: -$8.2MEPS: $-0.50View income statement →

Analyst Ratings & Price Target

Full Forecast
SellBuy
Buy2 analystsis grce a buy · grce analyst rating
Strong Buy
0
Buy
2
Hold
0
Sell
0
Strong Sell
0
12-Month Price Target
$4.00Low
$2.30Current
$4.00Avg Target73.91% upside
$4.00High
grce price target · grce 12 month forecast

Total: 2 · Buy rate: 100.0%

The GRCE analyst consensus is Buy, based on ratings from 2 Wall Street analysts over the past 3 months. The average 12-month price target is $4.00, representing +73.91% upside from the current price of $2.30.

Stock Performance

Full History
1D+0.00%
1W-5.35%
1M-1.71%
3M-41.48%
YTD-33.53%
1Y-27.22%
5Y-23.59%

About Grace Therapeutics, Inc.

CEOPrashant Kohli
IPO DateFeb 7, 2012
Employees4
CountryUS

Grace Therapeutics, Inc. specializes in the creation and commercialization of pharmaceutical products, primarily targeting uncommon and neglected diseases, with operations centered in Canada. The comp…

what is grace therapeutics, inc. · grce stock overview · grace therapeutics, inc. company profile · who is grace therapeutics, inc. ceo · grce NASDAQ · grace therapeutics, inc. headquarters · grace therapeutics, inc. business segments

About Stock Overview & Key Data

Grace Therapeutics, Inc. (GRCE) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Feb 7, 2012. As of the latest trading session, GRCE stock price is $2.30, with a market capitalization of $35.6M. The stock has returned -27.22% over the past 12 months and -33.53% year-to-date.

According to 2 Wall Street analysts, the consensus rating for Grace Therapeutics, Inc. stock is Buy, with an average 12-month price target of $4.00. In fiscal year 2025, Grace Therapeutics, Inc. reported revenue of — and net income of -$13.6M. For detailed data — including Grace Therapeutics, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.

Frequently Asked Questions

As of the latest trading session, Grace Therapeutics, Inc. (GRCE) stock price is $2.30. The stock is traded on NASDAQ under the ticker symbol GRCE. The 52-week range is $1.79 – $5.18.

GRCE stock priceGRCE quote todaylive ticker
Data provided by Financial Modeling PrepLast updated: Jun 9, 2026Not investment advice